Nasdaq:ATRA
Atara Biotherapeutics, Inc.
Clinical-stage biotechnology firm developing allogeneic cell therapies for autoimmune diseases with a notable 2024 revenue spike to $128.9M.
Key Metrics
Investment Thesis
Bull Case
Atara represents a high-risk, high-reward opportunity given the transformative potential of its allogeneic cell therapy platform for treating autoimmune diseases. The massive 15-fold revenue increase in 2024 suggests strong market adoption or significant milestone payments from licensing deals that could stabilize future cash flows. If clinical trials succeed, the company could become a major player in the growing cellular therapy market with minimal competition.
Bear Case
The stock is highly speculative due to the company's negative retained earnings of $2.05B and current liabilities exceeding assets by nearly $140M. Investors face the risk of dilution through share issuances of $9.3M as the company attempts to fund operations without generating sufficient positive cash flow from core activities. A failure to achieve regulatory approval or commercial milestones could lead to further losses and potential insolvency.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics is a clinical-stage biotechnology company focused on developing allogeneic cell therapies to treat autoimmune diseases and other conditions. The company operates primarily in the United States and Europe, leveraging its proprietary platform to manufacture off-the-shelf cellular medicines. Its recent financial profile reflects a significant revenue surge driven by commercialization efforts alongside substantial R&D investments.
Analysis
Management Discussion
While 2024 saw a dramatic increase in revenue to $128.9M compared to the prior year, this was accompanied by a net loss of $85.4M driven by elevated research and development costs of $151.5M. Operating cash flow from activities was negative at $68.7M, though financing activities provided $59.3M in inflows to offset operational burn. The company's ability to extend its runway depends on continued cost management and successful commercial execution.
Industry Overview
The biotechnology sector is characterized by long development cycles, high R&D expenditures, and reliance on successful clinical trials for product approval. Companies in this space often operate at a loss while building pipelines, with revenue dependent on licensing deals or sales of approved therapies. Regulatory hurdles from agencies like the FDA and EMA pose significant barriers to entry and can delay market access for new treatments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $8.6M | $128.9M |
| Cost of Revenue | $-63.6M | $0 | $0 |
| Gross Profit | $63.6M | $8.6M | $128.9M |
| Operating Expenses | $344.1M | $284.6M | $212.4M |
| Operating Income | $-280.5M | $-276.0M | $-83.4M |
| R&D | $272.5M | $224.8M | $151.5M |
| G&A | $71.6M | $50.9M | $39.9M |
| Stock-Based Comp | $53.8M | $45.4M | $27.0M |
| D&A | $5.7M | $4.8M | $5.1M |
| Depreciation | — | $3.7M | $2.7M |
| Other OpEx | $0 | $8.9M | $21.0M |
| Non-Operating Income | $52.2M | $-105.0K | $-2.0M |
| Interest Expense | — | $5.3M | $4.6M |
| Pre-Tax Income | $-228.3M | $-276.1M | $-85.4M |
| Income Tax | $12.0K | $15.0K | $-12.0K |
| Continuing Ops | $-228.3M | $-276.1M | $-85.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-228.3M | $-276.1M | $-85.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-228.3M | $-276.1M | $-85.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $295.1M | $101.9M | $64.9M |
| Cash & Equivalents | $92.9M | $25.8M | $25.0M |
| Marketable Securities | $149.9M | $25.9M | $17.5M |
| Accounts Receivable | $40.2M | $34.1M | $1.5M |
| Inventory | $1.6M | $9.7M | $10.7M |
| Other Current Assets | $10.5M | $6.3M | $10.3M |
| Long-Term Assets | $81.3M | $63.6M | $44.2M |
| PP&E (Net) | $6.3M | $3.9M | $1.3M |
| Operating Leases | $68.0M | $54.9M | $39.8M |
| Other LT Assets | $7.0M | $4.8M | $3.1M |
| Total Assets | $376.4M | $165.5M | $109.1M |
| Current Liabilities | $78.9M | $142.2M | $134.6M |
| Accounts Payable | $6.9M | $3.7M | $4.4M |
| Current Leases | $12.8M | $11.3M | $12.9M |
| Deferred Revenue | — | $77.8M | — |
| Other Current Liab | $51.8M | $30.4M | $111.3M |
| Long-Term Liabilities | $170.9M | $122.5M | $71.8M |
| LT Operating Leases | $58.1M | $45.7M | $29.9M |
| Other LT Liab | $112.8M | $39.3M | $41.9M |
| Total Liabilities | $249.8M | $264.7M | $206.4M |
| Shareholders' Equity | $126.6M | $-99.2M | $-97.3M |
| Retained Earnings | $-1.69B | $-1.97B | $-2.05B |
| AOCI | $-2.1M | $-204.0K | $8.0K |
| Total L&E | $376.4M | $165.5M | $109.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-228.3M | $-276.1M | $-85.4M |
| Non-Cash Adjustments | $-55.6M | $49.9M | $82.4M |
| Working Capital Changes | $13.5M | $33.3M | $-65.7M |
| Cash from Operations | $-270.4M | $-193.0M | $-68.7M |
| Capital Expenditures | $4.2M | $1.2M | $246.0K |
| Cash from Investing | $203.0M | $123.9M | $8.6M |
| Cash from Financing | $53.1M | $2.0M | $59.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-14.4M | $-67.1M | $-811.0K |
| Beginning Cash | $107.5M | $93.1M | $26.0M |
| Ending Cash | $93.1M | $26.0M | $25.2M |
Frequently Asked Questions
How does Atara Biotherapeutics, Inc. make money?
Primary revenue streams include commercial sales of approved or late-stage cell therapy products, licensing agreements with external partners, and government grants supporting clinical trial development. The company's financials also reflect significant operating expenses allocated to research and development ($151.5M) and general administration ($39.9M).
What are the main risks for ATRA?
Substantial net losses totaling $85.4M in 2024 indicate high burn rates that could deplete the $25.2M cash balance if commercialization does not accelerate. The company carries negative shareholders' equity of $97.3M and significant current liabilities of $134.6M, raising concerns about liquidity and solvency. Success is entirely dependent on clinical trial outcomes and regulatory approvals for new product candidates, with no guaranteed revenue diversification.
What is ATRA's competitive advantage?
The company possesses a proprietary platform for manufacturing standardized allogeneic cell therapies that reduce costs compared to autologous approaches. Atara benefits from a strong intellectual property portfolio protecting its core technologies in autoimmune disease treatment. Its ability to scale manufacturing efficiently is evidenced by significant revenue growth and controlled capital expenditures relative to cash flow.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.